Literature DB >> 19061425

Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential.

Eleuterio Lombardo1, Olga DelaRosa, Pablo Mancheño-Corvo, Ramón Menta, Cristina Ramírez, Dirk Büscher.   

Abstract

Human adipose-derived stem cells (hASCs) are mesenchymal stem cells with reduced immunogenicity and the capability to modulate immune responses. These properties make hASCs of special interest as therapeutic agents in the settings of chronic inflammatory and autoimmune diseases. Exogenous and endogenous toll-like receptor (TLR) ligands have been linked with the perpetuation of inflammation in a number of chronic inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis because of the permanent exposure of the immune system to TLR-specific stimuli. Therefore, hASCs employed in therapy are potentially exposed to TLR ligands, which may result in the modulation of hASC activity and therapeutic potency. In this study, we demonstrate that hASCs possess active TLR2, TLR3, and TLR4, because activation with specific ligands resulted in induction of nuclear factor kappa B-dependent genes, such as manganese superoxide dismutase and the release of interleukin (IL)-6 and IL-8. TLR3 and TLR4 ligands increased osteogenic differentiation, but no effect on adipogenic differentiation or proliferation was observed. Moreover, we show that TLR activation does not impair the immunogenic and immunosuppressive properties of hASCs. These results may have important implications with respect to the safety and efficacy of hASC-based cell therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19061425     DOI: 10.1089/ten.tea.2008.0340

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  49 in total

1.  Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

Authors:  Jeffery J Auletta; Robert J Deans; Amelia M Bartholomew
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

Review 2.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 3.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 4.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

5.  Stable changes in mesenchymal stromal cells from multiple myeloma patients revealed through their responses to Toll-like receptor ligands and epidermal growth factor.

Authors:  Meirav Pevsner-Fischer; Sarit Levin; Tal Hammer-Topaz; Yifat Cohen; Felix Mor; Gerard Wagemaker; Arnon Nagler; Irun Robert Cohen; Dov Zipori
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

Review 6.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

Review 7.  NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases.

Authors:  T-H Lin; J Pajarinen; L Lu; A Nabeshima; L A Cordova; Z Yao; S B Goodman
Journal:  Adv Protein Chem Struct Biol       Date:  2016-12-09       Impact factor: 3.507

Review 8.  Antenatal prevention of cerebral palsy and childhood disability: is the impossible possible?

Authors:  Stacey J Ellery; Meredith Kelleher; Peta Grigsby; Irina Burd; Jan B Derks; Jon Hirst; Suzanne L Miller; Larry S Sherman; Mary Tolcos; David W Walker
Journal:  J Physiol       Date:  2018-07-21       Impact factor: 5.182

9.  A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.

Authors:  Ruth S Waterman; Suzanne L Tomchuck; Sarah L Henkle; Aline M Betancourt
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

10.  Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood.

Authors:  Hyung-Sik Kim; Tae-Hoon Shin; Se-Ran Yang; Min-Soo Seo; Dong-Jae Kim; Soo-Kyung Kang; Jong-Hwan Park; Kyung-Sun Kang
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.